Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study

PURPOSE: RAS mutations occur in 12% to 27% of patients with acute myeloid leukemia (AML) and enhance sensitivity to cytarabine in vitro. We examined whether RAS mutations impact response to cytarabine in vivo. PATIENTS AND METHODS: One hundred eighty-five patients with AML achieving complete remissi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Neubauer, Andreas, Maharry, Kati, Mrózek, Krzysztof, Thiede, Christian, Marcucci, Guido, Paschka, Peter, Mayer, Robert J., Larson, Richard A., Liu, Edison T., Bloomfield, Clara D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2008
Gaiak:
Hematologic Malignancies
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653132/
https://ncbi.nlm.nih.gov/pubmed/18559876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.14.0418
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak